Conversely, administration of TCLPA5 at daily dosage of 2 mg/kg or 5 mg/kg remarkably attenuated these PASI scores (Figure 2b,c), indicating a pathogenic role of LPA5 in psoriasis. Here, LPAR5 is linked to psoriasis.